Endorectal HDR brachytherapy produced 80% initial response in frail rectal cancer
Short-course EBRT plus endorectal HDR brachytherapy produced 80% cCR/ncCR, but grade 3 late rectal toxicity occurred in 27%.
Latest research
Search the archiveClinicians underestimated urinary and bowel symptoms after prostate radiotherapy
HYPO-RT-PC showed persistently poor agreement between patient- and clinician-reported toxicity, particularly for urinary and bowel symptoms.
CBCT-measured muscle loss during RT predicted survival in HPV-positive oropharyngeal cancer
Routine treatment CBCT detected skeletal muscle loss that independently tracked worse survival in 337 patients with HPV-positive oropharyngeal cancer.
Modern fractionation data challenge fixed α/β assumptions across tumor types
A systematic review argues that α/β is disease- and context-specific rather than a fixed biological constant across radiotherapy settings.
Kidney proton SBRT needed a larger superior–inferior robustness margin
Kidney proton SBRT modeling supported 4-mm superior–inferior and 3-mm lateral/anterior–posterior positioning uncertainty with intrafraction repositioning.
Second malignancy risk reached 6.7% at 15 years after IMRT for nasopharyngeal cancer
Among long-term NPC survivors treated with IMRT, radiation-related second malignancy incidence reached 6.66% at 15 years.
Open-face masks improved head and neck RT experience without compromising setup accuracy
In the randomized OPEN trial, SGRT-supported open masks maintained setup accuracy while reducing distress and improving treatment experience.
Bayesian heart-dose constraints improved cardiac risk selection in NSCLC
Personalized Bayesian heart-dose limits improved identification of NSCLC patients at low risk of treatment-related cardiac troponin elevation.
Chemotherapy-free RT plus durvalumab was feasible in PD-L1-high locally advanced NSCLC
Concurrent durvalumab with either 60 Gy/15 or 60 Gy/30 was feasible in a 24-patient phase I study without concurrent chemotherapy.
ReCOG identifies major heterogeneity across pelvic re-irradiation trials
Nine prospective rectal and anal re-irradiation trials varied widely in dose, margins, cumulative-dose methods, organs at risk, and PRO reporting.
Adding CyberKnife SBRT to lenvatinib and tislelizumab tracked with longer survival in HCC
IPTW-weighted response was 71.1% versus 37.6%, with median survival 23.0 versus 15.6 months after adding SBRT.
MR-guided prostate re-irradiation achieved high early control but accumulating GU toxicity
Failure-free survival was 96.6% at 12 months, while grade 3 GU toxicity increased to 12.5% by one year.
Ablative MR-guided RT achieved 95% local control in GEP-NETs
Among 20 mostly metastatic GEP-NET patients, MR-guided ablative RT achieved 95% local control with acute grade 3 toxicity in 10%.
Perirenal hydrogel spacer reduced bowel dose in simulated kidney SBRT
In one cadaveric RCC plan, stable 1-cm perirenal separation reduced large-bowel Dmax from 34.5 to 22.1 Gy.
VMAT with a custom 3D bolus treated nasal BCC with low early toxicity
Seven patients completed 60 Gy with no recurrences, grade ≥3 skin toxicity, fibrosis, cartilage necrosis, or nasal contour deformation at early follow-up.